{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"ACTION-1","nct_id":"NCT05477576","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=action-1-nct05477576. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"ACTION-1","arms":[{"description":"Part 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design.","label":"Phase 1b - RYZ101","type":"EXPERIMENTAL"},{"description":"Actinium 225 radiolabeled somatostatin analog (SSA) for injection","label":"Phase 3 - RYZ101","type":"ACTIVE_COMPARATOR"},{"description":"Investigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.","label":"Phase 3 - Standard of Care","type":"ACTIVE_COMPARATOR"},{"description":"Actinium 225 radiolabeled somatostatin analog (SSA) for injection","label":"Phase 3 - RYZ101, PK/ECG Substudy adhoc subcohort","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET"],"enrollment":{"count":343,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"RYZ101","type":"DRUG"},{"name":"Everolimus","type":"DRUG"},{"name":"Sunitinib","type":"DRUG"},{"name":"Octreotide","type":"DRUG"},{"name":"Lanreotide","type":"DRUG"}],"last_update":"2026-10-05","lead_sponsor":"RayzeBio, Inc.","official_title":"Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1b: RP3D","timeFrame":"56 days of study treatment"},{"measure":"Phase 3: PFS as determined by BICR","timeFrame":"After the target number of 143 PFS events have occurred"}],"references":[{"citation":"Taunk NK, Escorcia FE, Lewis JS, Bodei L. Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets. Cancer J. 2024 May-Jun 01;30(3):218-223. doi: 10.1097/PPO.0000000000000720.","pmid":"38753757","type":"DERIVED"}],"start_date":{"date":"2022-03-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","url":"https://clinicaltrials.gov/study/NCT05477576"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/action-1-nct05477576"}